Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Diffuse Large B-cell Lymphoma Patients with Failure of CAR-T Therapy

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Diffuse Large B-cell Lymphoma Patients with Failure of CAR-T Therapy

2024.04.10
In the challenging field of hematology, the search for effective treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) after CAR-T therapy failure is crucial. Professor Professor Haiwen Huang from The First Affiliated Hospital of Soochow University leads an innovative study exploring allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a promising alternative. This collaborative research not only offers new hope for R/R DLBCL patients but also showcases the pioneering spirit driving advancements in oncology. By providing valuable insights into allo-HSCT's potential, Professor Huang and his team contribute significantly to the evolving landscape of cancer treatment, highlighting the importance of innovation and teamwork in improving patient care.
Professor Huilai Zhang : Diligently Striving to Improve Survival Time and Quality of Life for Lymphoma Patients in China | 2024 CSCO Hematology

Professor Huilai Zhang : Diligently Striving to Improve Survival Time and Quality of Life for Lymphoma Patients in China | 2024 CSCO Hematology

2024.03.06
Lymphoma is one of the fastest-growing malignant tumors worldwide, and the incidence rate in China has been gradually increasing in recent years, posing a serious threat to the health of the population. From January 26 to 28, 2024, the "Work Conference of the Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee of the Chinese Society of Clinical Oncology (CSCO) and the 2024 CSCO Academic Conference on Hematology, Lymphoma, and Myeloma Diseases" was successfully held in Haikou. Professor Huilai Zhang from Tianjin Medical University Cancer Institute and Hospital shared insights at the conference on the survival status and diagnosis and treatment strategies for patients with indolent lymphoma, frontline treatment strategies for mantle cell lymphoma, and research progress on immunosuppressants. Following the conference, Oncology Frontier - Hematology Frontier invited Professor Zhang for an in-depth sharing session.
Professor Shuye Wang: Emphasizing early diagnosis and treatment of systemic amyloidosis to improve patient cure rates | 2024 CSCO Hematology Academic

Professor Shuye Wang: Emphasizing early diagnosis and treatment of systemic amyloidosis to improve patient cure rates | 2024 CSCO Hematology Academic

2024.03.06
Due to its low incidence and diverse clinical manifestations, patients with AL amyloidosis are often misdiagnosed or underdiagnosed, resulting in insufficient treatment. From January 26th to 28th, 2024, the "China Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference" was successfully held in Haikou. During the conference, Professor Shuye Wang from the First Affiliated Hospital of Harbin Medical University shared insights with Oncology Frontier - Hematology Frontier on the current status of diagnosis and treatment of systemic amyloidosis, perspectives on early diagnosis, and the future research plans of his team.
Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology

Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology

2024.03.05
In the era of medical innovation, various targeted and immune drugs are emerging, leading to breakthroughs in lymphoma treatment. From January 26th to 28th, 2024, the "Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, as well as the 2024 CSCO Hematology and Lymphoma, and Myeloma Disease Academic Conference" was grandly held in the beautiful city of Haikou. At the conference, experts of all ages from both domestic and international arenas engaged in discussions and exchanges on the latest developments and hot topics in lymphoma diagnosis and treatment. "Oncology Frontier - Hematology Frontier" had the privilege to interview Professor Aichun Liu, Director of the Department of Hematology and Lymphoma at Harbin Medical University Cancer Hospital, regarding his perspectives and opinions on the overall treatment strategy for relapsed/refractory B-cell lymphoma, as well as sharing his team's research plans and management experiences in lymphoma.
ASH Big Shot Interview | Professor Jie Jin : IL1RAP-TCE Antibody Effectively Eliminates Leukemia Stem Cells in AML

ASH Big Shot Interview | Professor Jie Jin : IL1RAP-TCE Antibody Effectively Eliminates Leukemia Stem Cells in AML

2024.01.05
From December 9 to 12, 2023, the 65th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, in a hybrid format combining online and offline sessions. As one of the largest and most comprehensive international academic conferences in the field of hematology, experts and scholars from around the world gathered to explore the latest frontiers in hematologic diseases, new treatment methods and strategies, and disease management approaches. At this year's ASH Annual Meeting, Professor Jin Jie and her team from the First Affiliated Hospital of Zhejiang University School of Medicine presented an oral report titled "IL1RAP-Specific T Cell Engager (TCE) Antibody Effectively Clears Leukemia Stem Cells (LSC) in Acute Myeloid Leukemia (AML)." "Tumor Watch" had the privilege of interviewing Professor Jin Jie on-site to discuss the research and its related content.
“Optimizing Allo-HSCT Preconditioning Strategies for R/R AML and Elderly Myeloid Tumor Patients: Insights from Prof. Jiang Erlie’s Team”

“Optimizing Allo-HSCT Preconditioning Strategies for R/R AML and Elderly Myeloid Tumor Patients: Insights from Prof. Jiang Erlie’s Team”

2024.01.04
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) stands as a pivotal treatment for malignant hematological diseases. The preconditioning phase plays a crucial role in the overall transplantation process, influencing the eradication of residual tumor cells, enhancing transplant success rates, and reducing post-transplant complications and relapse rates. At the 65th Annual Meeting of the American Society of Hematology (ASH) in 2023, Professor Jiang Erlie's team from the Hematology Hospital of the Chinese Academy of Medical Sciences presented two studies focusing on optimizing and exploring preconditioning regimens for allo-HSCT in relapsed/refractory acute myeloid leukemia (R/R AML) and elderly myeloid tumor patients. This article shares the key findings and clinical significance of these two studies.